Clinical Trials Directory

Trials / Completed

CompletedNCT04646993

WHITE Study: WHIch Decision After a First Venous ThromboEmbolism?

Which Decision After a First Venous Thromboembolism? The WHITE Study

Status
Completed
Phase
Study type
Observational
Enrollment
1,200 (actual)
Sponsor
Arianna Anticoagulazione Foundation · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The WHITE study is a multicenter, multinational, investigators-initiated, observational, prospective study conducted in a consecutive series of ambulatory patients who had completed the recommended or practicable period of anticoagulation after a first-ever episode of venous thromboembolism (VTE) The general aim of the study is to evaluate the distribution of decisions and of the reasons guiding the physician's decision on the modality to manage the secondary prevention of VTE in patients treated for a first-ever episode of VTE, after the initial 3-12 months of anticoagulant therapy.

Detailed description

The WHITE study is an international, non-profit, multicenter, observational, prospective and no profit study 3,200 subjects having experienced a first-ever episode of DVT of the lower limbs and/or PE, receive anticoagulation therapy for a period as recommended by international and/or local practice guidelines will be enrolled across all the countries participating to the study. When this recommended period expires, the attending physician has to decide whether to continue with anticoagulation, switch to anti-thrombotic of another class, or stop any prophylactic pharmacological treatment. The primary objective of the study is the evaluation of the distribution of decisions and of the reasons guiding the physician's decision on the modality to manage the secondary prevention of VTE in patients treated for a first-ever episode of VTE, after the initial 3-12 months of anticoagulation therapy. The secondary objective is the collection of data during the follow-up: the frequency of thromboembolic complications, of bleeding complications, or death from any cause.

Conditions

Timeline

Start date
2018-02-01
Primary completion
2021-12-30
Completion
2022-02-28
First posted
2020-11-30
Last updated
2022-03-11

Locations

1 site across 1 country: Czechia

Source: ClinicalTrials.gov record NCT04646993. Inclusion in this directory is not an endorsement.